Comparing CT and MRI with VI-RADS for Bladder Cancer Staging
Official title: Prospective Diagnostic Accuracy Study Comparing CT and MRI (VI-RADS) for Local Staging of Newly Diagnosed Bladder Cancer
Run by Oslo University Hospital · NCT07602010 · Data updated 2026-11-12
This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Status | Recruiting |
| Started | April 22, 2026 |
| Main results expected | April 30, 2028 |
| Study ends | October 31, 2028 |
| Registry record updated | May 22, 2026 |
| Trial ID | NCT07602010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with newly diagnosed bladder cancer who are scheduled for TURBT or cystectomy within 6 weeks and can receive both CT and MRI.
✕Probably not a fit
Patients unable to undergo MRI or iodinated contrast, or those with lesions that are non-malignant or located outside the bladder, may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center diagnostic study compares two imaging methods—contrast-enhanced CT and multiparametric MRI using VI-RADS—for local staging of newly diagnosed bladder cancer. Each participant undergoes both imaging tests before TURBT or cystectomy, and histopathology serves as the reference standard. Two radiologists read the images in blinded fashion, and the results are analyzed with paired statistics to compare accuracy and interobserver agreement. The goal is to determine which modality or approach provides more reliable information to guide treatment decisions between non-muscle-invasive and muscle-invasive disease.
Why it matters
Potential benefit: If successful, the study could indicate which imaging approach offers higher accuracy for local staging, potentially influencing preoperative planning and patient management.
How similar studies have gone: Prior retrospective and meta-analytic work suggested MRI with VI-RADS may outperform CT for local staging, but prospective paired evidence is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Newly diagnosed bladder cancer on cystoscopy * Planned TURBT or cystectomy within 6 weeks * Eligible for both CT and MRI within 6 weeks * Written informed consent provided Exclusion Criteria: * Contraindications to MRI or iodinated contrast media * Prior treatment for bladder cancer * Pregnancy * Non-malignant bladder lesions * Tumors located in bladder diverticula
Where it's running
-
Oslo University Hospital
Oslo, Norway Recruiting
Study contacts
- Principal investigator: Andreas Habberstad, MD, PhD — Oslo University Hospital
- Study coordinator: Study Coordinator, Department of Urology
- Email: postmottak@ous-hf.no
- Phone: +47 22 89 40 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
Blood test for detecting tumor DNA in bladder and upper tract cancer
A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.
-
Specimen Collection for Validation of a New urine-based bladder cancer test
This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.
-
Adding targeted stereotactic body radiation therapy to standard systemic treatment for people with oligometastatic urothelial (bladder) carcinoma.
This study will test whether adding stereotactic body radiation therapy (SBRT) to usual systemic treatment helps people with urothelial (bladder) cancer who have up to three extracranial metastases.
-
IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors
This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.
-
Home IV fluid infusions after radical cystectomy
This trial will test whether giving home IV fluids after radical cystectomy for bladder cancer reduces 90-day hospital readmissions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.